Biophytis S.A.
ALBPS | PA
Overview
Corporate Details
- ISIN(s):
- FR0012816825 (+4 more)
- LEI:
- 9695008GIE061NBGU106
- Country:
- France
- Address:
- 14 AVENUE DE L'OPERA, 75001 PARIS
- Website:
- https://www.biophytis.com/en/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Biophytis S.A. is a clinical-stage biotechnology company that develops therapeutics aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients with age-related diseases. The company's therapeutic approach targets and activates key biological resilience pathways to counteract stresses leading to these conditions. Its pipeline features orally administered small molecules, with the lead candidate, BIO101 (20-hydroxyecdysone), in development for neuromuscular diseases such as sarcopenia and Duchenne Muscular Dystrophy (DMD). A second candidate, Macuneos (BIO201), targets retinal diseases, including dry Age-related Macular Degeneration (AMD) and Stargardt disease. The company is also actively developing therapies for obesity, with a focus on preserving muscle mass during weight loss, and utilizes AI partnerships to accelerate its drug discovery efforts.
Stop Scraping. Start Analyzing.
You're viewing a fraction of the data available for Biophytis S.A..
Get complete, real-time, and AI-ready data via the API the pros use.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-06-04 07:00 |
Regulatory News Service
Biophytis announces its participation in the BIO International Convention from …
|
English | 155.1 KB | |
| 2025-06-04 07:00 |
Regulatory News Service
Biophytis annonce sa participation à la BIO International Convention du 16 au 1…
|
French | 161.2 KB | |
| 2025-05-30 22:00 |
Report Publication Announcement
Information on the Annual Financial Statements
|
English | 103.8 KB | |
| 2025-05-30 22:00 |
Report Publication Announcement
Information sur les comptes annuels
|
French | 172.5 KB | |
| 2025-05-15 07:00 |
Environmental & Social Information
Biophytis Highlights Innovative Approach to Obesity Treatment During Key ECO 20…
|
English | 144.3 KB | |
| 2025-05-15 07:00 |
Regulatory News Service
Biophytis met en lumière son approche innovante du traitement de l’obésité lors…
|
French | 129.9 KB | |
| 2025-04-22 07:00 |
Regulatory News Service
Biophytis cible la restauration de la mobilité chez les patients obèses
|
French | 143.1 KB | |
| 2025-04-22 07:00 |
Earnings Release
Biophytis targets mobility restoration in patients with obesity
|
English | 140.1 KB | |
| 2025-04-09 07:00 |
Regulatory News Service
Biophytis Confirms the Launch of the Phase 2 OBA Clinical Trial in Obesity
|
English | 175.0 KB | |
| 2025-04-09 07:00 |
Regulatory News Service
Biophytis confirme le lancement de l’essai clinique de Phase 2 OBA dans l’obési…
|
French | 169.7 KB | |
| 2025-03-28 22:00 |
Share Issue/Capital Change
Biophytis announces the settlement and delivery of its €2.6 million private pla…
|
English | 534.3 KB | |
| 2025-03-28 22:00 |
Share Issue/Capital Change
Biophytis annonce le règlement-livraison de son placement privé de 2,6 millions…
|
French | 340.2 KB | |
| 2025-03-26 07:35 |
Share Issue/Capital Change
Biophytis announces the successful completion of a €2,6 million private placeme…
|
English | 381.7 KB | |
| 2025-03-26 07:35 |
Share Issue/Capital Change
Biophytis annonce le succès d'un placement privé d'environ 2,6 millions d'euros
|
French | 381.0 KB | |
| 2025-03-24 07:30 |
Regulatory News Service
Biophytis announces new non-clinical data further supporting its mission to pio…
|
English | 242.6 KB |
Automate Your Workflow. Get a real-time feed of all Biophytis S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for Biophytis S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-11-22 | N/A | Other | Buy | 8,443,190 | 79,365.99 EUR |
| 2020-12-16 | N/A | Other | Sell | 500,000 | 499,000.00 EUR |
| 2020-12-16 | N/A | Other | Other | 313,417 | N/A |
| 2020-04-30 | N/A | Other | Other | 2,955,701 | 177,342.06 EUR |
